It is reported that the medical department of Siemens is suspected of bribing hospitals in China to use its high-priced medical products and was investigated by the State Administration for Industry and Commerce.
According to the Beijing Business Daily reported on May 4, the news said that the State Administration for Industry and Commerce accused Siemens and its distributors of using the free supply of medical equipment in exchange for the exclusive use of chemical reagents developed by Siemens on the equipment. Article 8 of China's "Anti-Unfair Competition Law" is suspected of bribery. The bribery incident that was exposed this time involved a variety of medical equipment including blood test equipment, and there were as many as 1,000 hospitals involved.
It is understood that the State Administration for Industry and Commerce has been investigating the alleged bribery of hospitals using high-priced medical products from Siemens last year, but the investigation has never been known before.
This is not the first time Siemens Medical has been exposed to bribes in China. According to the US Department of Justice document, from March 2001 to September 2007, Siemens spent about $1.4 billion to pay bribes around the world to win infrastructure contracts. The departments involved in commercial bribery in China include Siemens Medical. It paid about $14.4 million to pay bribes to five Chinese hospitals and received nearly $300 million in medical equipment orders. For this reason, Siemens paid a fine of over US$1.3 billion to the US and German governments.
Last year, the multinational pharmaceutical company GlaxoSmithKline was fined 3 billion yuan in bribery in China, becoming the biggest fine for Chinese pharmaceutical companies to date.
The industry believes that the penalties and regulations of the relevant national departments on Siemens, GlaxoSmithKline and other international medical giants are expected to bring opportunities to the domestic medical device industry . According to previous media reports, China's conventional medical devices have basically achieved independent production, and high-end medical devices have also been involved.
Bohai Securities said that it is recommended to select stocks from the domestic medical device industry with several main lines: First, as the population ages, the related cardiovascular and health monitoring products will benefit for a long time. Strategic execution, building a health care industry-wide industrial chain platform in the cardiovascular industry, and actively deploying Lepu Medical for telemedicine, leading domestic companies in the field of blood glucose monitoring, and Sannuo Bio at the current hospital market; Second, grassroots and non-public The medical device market in medical institutions is vast, and the market for home medical devices will also grow rapidly. The key recommendations are: a full range of medical device products, obvious advantages in home medical device channels, and actively deploying e-commerce channels and Internet health management services. Third, with the advent of the intelligent hardware era, the intelligentization of home medical devices will surely become the future development trend. Key recommendations: Jiu'an Medical, a leading company in the field of mobile medical intelligent hardware; Fourth, future high-end medical equipment The localization process will continue to accelerate, with emphasis Recommended: the layout of high-end color Doppler ultrasound, POCT blood gas analyzer, POCT cardiac markers magnetic field beginning to bear results of state management instruments.
Others Air Dryer,Small Air Dryer,Refrigerated Compressed Air Dryer,Dryer Compressor
Hangzhou Zhongju air separation equipment manufacturing Co., Ltd , https://www.hzzjkfzz.com